Arpeflu, 100 mg 30 pcs.

Pharmacotherapeutic group:antiviral and immunomodulatory agent.

ATX code: [L03AX].

Pharmacological action

Pharmacodynamics

. Antiviral agent, has immunomodulatory and anti-influenza action, specifically suppresses influenza A and B viruses.

It has interferon-inducing properties and stimulates humoral and cellular immune reactions, phagocytic function of macrophages and increases resistance of the body to viral infections. It prevents the development of post-flu complications, reduces the frequency of exacerbations of chronic diseases, normalizes immunological parameters. Its antiviral effect is due to the suppression of fusion of the lipid shell of the virus with the cell membranes when the virus comes into contact with the cell.

Therapeutic effectiveness in influenza is shown in reduction of intoxication and severity of catarrhal symptoms, shortening of fever periods and overall duration of the disease. It belongs to low-toxic medicines (1L>50>4 g/kg). It does not have any negative effect on human body when administered orally in recommended doses.

Pharmacokinetics

Absorption is fast. Rapidly distributed to organs and tissues. Time to reach maximum concentration (T_Cti) when administered at a dose of 50 mg – 1.2 h, 100 mg – 1.5 h. It is metabolized in the liver. The elimination half-life (T_1D) is 17-21 h. About 40% is excreted unchanged, mainly with bile (38.9%) and in small amount with kidneys (0.12%). During the first day 90% of the administered dose is excreted.

Indications

Prevention and treatment in adults and children: flu caused by viruses A and B, acute respiratory viral infections (ARI) (including those complicated by bronchitis, pneumonia); secondary immunodeficiency states.

The complex therapy of chronic bronchitis, pneumonia and recurrent herpetic infection. Prevention of postoperative infectious complications and normalization of immune status in adults.

Active ingredient

Composition

One film-coated tablet contains:

Active ingredient: Umifenovir hydrochloride monohydrate in terms of umifenovir hydrochloride – 50 mg or 100 mg;

Auxiliary substances: povidone (plasdon K-17), 0.66 mg or 1.32 mg; microcrystalline cellulose, 34.0 mg or 68.0 mg; pregelatinized starch (starch – 1500), 4.5 mg or 9.0 mg; magnesium stearate, 1.5 mg or 3.0 mg; Colloidal silica (aerosil) -1.5 mg or 3.0 mg; lactose sugar (lactose monohydrate) – to make a coated tablet weighing 150.0 mg or 300.0 mg.

Shell composition: opadray II white consisting of: talc (0.89 mg or 1.78 mg), macrogol (1.23 mg or 2.46 mg), titanium dioxide (1.5 mg or 3.0 mg), polyvinyl alcohol (2.38 mg or 4.76 mg) – to make a coated tablet of 156 mg or 312 mg.

How to take, the dosage

Ingestion, before meals. A single dose: for children from 3 to 6 years – 50 mg, from 6 to 12 years – 100 mg, over 12 years and adults – 200 mg (2 tablets of 100 mg or 4 tablets of 50 mg).

For non-specific prophylaxis

Treatment

Special Instructions

Synopsis

Contraindications

Side effects

Allergic reactions.

Interaction with other medicinal products

No adverse effects have been noted when prescribed with other medicinal products.

Similarities